Elevated lymphotoxin-α (TNFβ) is associated with intervertebral disc degeneration.
Cytokine
Inflammatory response
Intervertebral disc degeneration
Lymphotoxin-α
TNFβ
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
13 Jan 2021
13 Jan 2021
Historique:
received:
05
05
2020
accepted:
28
12
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Intervertebral disc degeneration (IVDD) is a primary cause of degenerative disc diseases; however, the mechanisms underlying the degeneration remain unclear. The immunoinflammatory response plays an important role in IVDD progression. The inflammatory cytokine lymphotoxin-α (LTα), formerly known as TNFβ, is associated with various pathological conditions, while its role in the pathogenesis of IVDD remains elusive. Real-time quantitative polymerase chain reaction (RT-qPCR), Western blotting (WB), and enzyme-linked immunosorbent assays were used to assess the levels of LTα in human nucleus pulposus (NP) tissues between degeneration and control groups. The plasma concentrations of LTα and C-reactive protein (CRP) were compared between healthy and IVDD patients. Rat primary NP cells were cultured and identified via immunofluorescence. Methyl-thiazolyl-tetrazolium assays and flow cytometry were used to evaluate the effects of LTα on rat NP cell viability. After NP cells were treated with LTα, degeneration-related molecules (Caspase-3, Caspase-1, matrix metalloproteinase (MMP) -3, aggrecan and type II collagen) were measured via RT-qPCR and WB. The levels of both the mRNA and protein of LTα in human degenerated NP tissue significantly increased. Plasma LTα and CRP did not differ between healthy controls and IVDD patients. Rat primary NP cells were cultured, and the purity of primary NP cells was > 90%. Cell experiments showed inversely proportional relationships among the LTα dose, treatment time, and cell viability. The optimal conditions (dose and time) for LTα treatment to induce rat NP cell degeneration were 5 μg/ml and 48 ~ 72 h. The apoptosis rate and the levels of Caspase-3, Caspase-1, and MMP-3 significantly increased after LTα treatment, while the levels of type II collagen and aggrecan were decreased, and the protein expression levels were consistent with their mRNA expression levels. This study demonstrated that elevated LTα is closely associated with IVDD and that LTα may induce NP cell apoptosis and reduce important extracellular matrix (ECM) proteins, which cause adverse effects on IVDD progress. Moreover, the optimal conditions for LTα treatment to induce NP cell degeneration were determined.
Sections du résumé
BACKGROUND
BACKGROUND
Intervertebral disc degeneration (IVDD) is a primary cause of degenerative disc diseases; however, the mechanisms underlying the degeneration remain unclear. The immunoinflammatory response plays an important role in IVDD progression. The inflammatory cytokine lymphotoxin-α (LTα), formerly known as TNFβ, is associated with various pathological conditions, while its role in the pathogenesis of IVDD remains elusive.
METHODS
METHODS
Real-time quantitative polymerase chain reaction (RT-qPCR), Western blotting (WB), and enzyme-linked immunosorbent assays were used to assess the levels of LTα in human nucleus pulposus (NP) tissues between degeneration and control groups. The plasma concentrations of LTα and C-reactive protein (CRP) were compared between healthy and IVDD patients. Rat primary NP cells were cultured and identified via immunofluorescence. Methyl-thiazolyl-tetrazolium assays and flow cytometry were used to evaluate the effects of LTα on rat NP cell viability. After NP cells were treated with LTα, degeneration-related molecules (Caspase-3, Caspase-1, matrix metalloproteinase (MMP) -3, aggrecan and type II collagen) were measured via RT-qPCR and WB.
RESULTS
RESULTS
The levels of both the mRNA and protein of LTα in human degenerated NP tissue significantly increased. Plasma LTα and CRP did not differ between healthy controls and IVDD patients. Rat primary NP cells were cultured, and the purity of primary NP cells was > 90%. Cell experiments showed inversely proportional relationships among the LTα dose, treatment time, and cell viability. The optimal conditions (dose and time) for LTα treatment to induce rat NP cell degeneration were 5 μg/ml and 48 ~ 72 h. The apoptosis rate and the levels of Caspase-3, Caspase-1, and MMP-3 significantly increased after LTα treatment, while the levels of type II collagen and aggrecan were decreased, and the protein expression levels were consistent with their mRNA expression levels.
CONCLUSIONS
CONCLUSIONS
This study demonstrated that elevated LTα is closely associated with IVDD and that LTα may induce NP cell apoptosis and reduce important extracellular matrix (ECM) proteins, which cause adverse effects on IVDD progress. Moreover, the optimal conditions for LTα treatment to induce NP cell degeneration were determined.
Identifiants
pubmed: 33441130
doi: 10.1186/s12891-020-03934-7
pii: 10.1186/s12891-020-03934-7
pmc: PMC7807514
doi:
Substances chimiques
Aggrecans
0
Collagen Type II
0
Lymphotoxin-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Subventions
Organisme : Postdoctoral Science Foundation of China
ID : 2019M652329
Organisme : Applied Basic Research Project of Qingdao
ID : 19-6-2-51-cg
Organisme : Taishan Scholars Program
ID : tsqn201909190
Organisme : National Natural Science Foundation of China
ID : 81772412
Organisme : Youth Fund Project of the Affiliated Hospital of Qingdao University
ID : 2017
Organisme : Shandong Provincial Science Foundation, China
ID : ZR2019BH084
Organisme : National Natural Science Foundation of China
ID : 81802190
Organisme : NIA NIH HHS
ID : P30 AG028740
Pays : United States
Organisme : Shandong Medical and Health Technology Development Plan Project
ID : 2017WS033
Références
Joint Bone Spine. 2000;67(5):452-5
pubmed: 11143913
Int J Nanomedicine. 2018 Jun 18;13:3493-3506
pubmed: 29950831
J Orthop Sci. 2006 Mar;11(2):191-7
pubmed: 16568393
Acta Biochim Biophys Sin (Shanghai). 2005 Nov;37(11):719-27
pubmed: 16270150
Eur Spine J. 2009 Nov;18(11):1573-86
pubmed: 19466462
Int J Mol Med. 2016 Jun;37(6):1439-48
pubmed: 27121482
Spine (Phila Pa 1976). 2005 Sep 1;30(17):1940-8
pubmed: 16135983
Cell Death Differ. 1999 Feb;6(2):99-104
pubmed: 10200555
Anat Rec (Hoboken). 2015 Apr;298(4):720-6
pubmed: 25284686
Int J Clin Exp Pathol. 2013 May 15;6(6):1009-14
pubmed: 23696917
Spine (Phila Pa 1976). 1998 Apr 15;23(8):849-55; discussion 856
pubmed: 9580950
Annu Rev Immunol. 2005;23:787-819
pubmed: 15771586
Spine (Phila Pa 1976). 2005 Sep 1;30(17):1973-8
pubmed: 16135988
Einstein (Sao Paulo). 2019 Aug 29;17(4):eAO4637
pubmed: 31482941
Blood. 2012 Jan 19;119(3):651-65
pubmed: 22053109
Spine (Phila Pa 1976). 2006 Jun 15;31(14):1522-31
pubmed: 16778683
Biochem Soc Trans. 2007 Aug;35(Pt 4):652-5
pubmed: 17635113
Blood. 2010 Jan 7;115(1):122-32
pubmed: 19789388
J Cell Mol Med. 2018 Nov;22(11):5539-5551
pubmed: 30207057
Curr Opin Rheumatol. 2002 May;14(3):204-11
pubmed: 11981314
Asian Spine J. 2016 Oct;10(5):843-849
pubmed: 27790311
Ann Rheum Dis. 2011 Apr;70(4):583-9
pubmed: 21330639
Histol Histopathol. 2017 Jun;32(6):523-542
pubmed: 27848245
Asian Spine J. 2009 Jun;3(1):39-44
pubmed: 20404946
Lancet. 1999 Aug 14;354(9178):581-5
pubmed: 10470716
JOR Spine. 2018 Jun;1(2):
pubmed: 29963655
Osteoarthritis Cartilage. 2015 Jul;23(7):1057-70
pubmed: 25827971
Arthritis Res Ther. 2013;15(6):R202
pubmed: 24283517
Inflamm Res. 2018 Jun;67(6):495-501
pubmed: 29541795
Spine (Phila Pa 1976). 2001 Sep 1;26(17):1873-8
pubmed: 11568697
Int J Mol Sci. 2016 Sep 27;17(10):
pubmed: 27689996
Cytokine Growth Factor Rev. 2014 Apr;25(2):83-9
pubmed: 24636534
Blood. 1995 May 15;85(10):2779-85
pubmed: 7742538
Rheumatology (Oxford). 2009 Nov;48(11):1447-50
pubmed: 19748963
Ann Rheum Dis. 2004 Oct;63(10):1344-6
pubmed: 15033655
J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:3-9
pubmed: 16595435
World Neurosurg. 2013 Nov;80(5):e131-3
pubmed: 22705752
Surg Radiol Anat. 2018 Sep;40(9):1055-1061
pubmed: 29876634
BMC Musculoskelet Disord. 2020 Jun 2;21(1):339
pubmed: 32487144
J Orthop Res. 2015 Mar;33(3):294-303
pubmed: 25336289
Eur Spine J. 2016 Jan;25(1):80-95
pubmed: 26188769